926293-55-2

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
6-Bromo-2-methylpyridine-3-carboxaldehyde is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals for its ability to contribute to the development of new and effective compounds.
Used in Organic Synthesis:
6-Bromo-2-methylpyridine-3-carboxaldehyde is used as a building block in organic synthesis for the production of pyridine derivatives, which are important in the creation of a wide range of chemical products.
Used as a Reagent in Organic Reactions:
In the field of organic chemistry, 6-Bromo-2-methylpyridine-3-carboxaldehyde is used as a reagent, particularly in the synthesis of heterocyclic compounds and in the preparation of complex molecules for medicinal chemistry research, due to its reactive functional groups.
Used in Dyes and Pigments Development:
6-Bromo-2-methylpyridine-3-carboxaldehyde is used in the development of dyes and pigments, where its chemical properties contribute to the creation of new colorants with specific characteristics.
Used in Materials Science:
In the field of materials science, 6-Bromo-2-methylpyridine-3-carboxaldehyde is utilized for its potential applications in the development of new materials with unique properties, such as in the creation of advanced polymers or other composite materials.

Upstream product

• 39919-65-8 2,5-dibromo-6-methylpyridine 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 926305-05-7 6-(4-methoxy-phenoxy)-2-methyl-pyridine-3-carbaldehyde 
• 926305-06-8 6-(4-methoxy-phenylsulfanyl)-2-methyl-pyridine-3-carbaldehyde 
• 926295-88-7 [4-(5-formyl-6-methyl-pyridin-2-yloxy)-phenyl]-acetic acid methyl ester 
• 1227576-36-4 (6-bromo-2-methylpyridin-3-yl)methanol 
• 1060805-97-1 6-bromo-2-methylpyridine-3-carboxylic acid 
• 926295-40-1 methyl 4-[(5-formyl-6-methylpyridin-2-yl)sulfanyl]benzoate 
• 1446818-14-9 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-6-(2-methylphenyl)pyridin-3-yl]methyl]piperazine-1-carboxylate 

Relevant academic research and scientific papers

MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS

The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.

Protein kinase inhibitor and its preparation method and medical application

The invention provides a compound shown in the structural formula I or its tautomer, mesomer, racemate, enantiomer, diastereoisomer or their mixture, or a pharmaceutically acceptable salt or solvate of the compound shown in the structural formula I or its tautomer, mesomer, racemate, enantiomer, diastereoisomer or their mixture. The ring A, R1, R2, R3 and R4 are defined in the specification. The invention also provides a preparation method of the compound shown in the structural formula I and a use of the compound in preparation of a drug for treating cell proliferative disorder.

PYRIDYLPYRIDONE DERIVATIVE USEFUL AS A RET KINASE INHIBITOR IN THE TREATMENT OF IBS AND CANCER

This invention relates to a novel compound which is an inhibitor of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing it, to processes for its preparation, and to its use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity. Formula (I)

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).